Lung cancer is the number one cause of cancer deaths globally. In China, over one million people get lung cancer each year, and for six hundred thousand the disease is terminal. In one of the largest worldwide markets Helen Chen, L.E.K.’s Managing Partner for China, has led hundreds of healthcare and life sciences projects. In this case study, Helen discusses how L.E.K. advised a leading pharmaceutical company in their pricing and successful launch of a critical lung cancer drug to the Chinese market.

Related Insights